UPDATE - LifeMD Reports Second Quarter 2026 Results

UPDATE this press release has been updated to remove a duplicate table. * Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. * Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications. * Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy. * Weight Management Program subscribers grew to approximately 108,000 at quarter end; total active subscribers increased 20% year-over-year to approximately 356,000. * Women’s Health operating trends continues to improve, with lower customer acquisition costs and a broad set of new pharmacy products launching in the second half. * Launched an exclusive telehealth co-marketing collaboration with Halozyme’s wholly-owned subsidiary, Antares Pharma, Inc., for XYOSTED®, the only FDA-approved, once-weekly subcutaneous testosterone auto-injector — with additional strategic partnerships and enterprise relationships advancing toward execution in the second half of 2026. * Exited the quarter with $25.1 million of cash, no debt, and $30 million of additional liquidity under its revolving credit facility. * Expecting a return to positive adjusted EBITDA in the second half of 2026 and an expected fourth quarter exit revenue run rate of approximately $250 million and approximately $22 million of annualized adjusted EBITDA * Revising full year 2026 guidance to revenue of $205.5 million to $212.5 million and adjusted EBITDA of negative $6.0 million to breakeven, including $2 million to $3 million of net launch costs for XYOSTED® in 2026. Conference call begins at 4:30 p.m. Eastern time today